222 related articles for article (PubMed ID: 27374736)
41. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
[TBL] [Abstract][Full Text] [Related]
42. [Misoprostol: off-label use in the first trimester of pregnancy (spontaneous abortion, and voluntary medical termination of pregnancy)].
Beucher G; Dolley P; Carles G; Salaun F; Asselin I; Dreyfus M
J Gynecol Obstet Biol Reprod (Paris); 2014 Feb; 43(2):123-45. PubMed ID: 24433988
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness and safety of early medication abortion provided in pharmacies by auxiliary nurse-midwives: A non-inferiority study in Nepal.
Rocca CH; Puri M; Shrestha P; Blum M; Maharjan D; Grossman D; Regmi K; Darney PD; Harper CC
PLoS One; 2018; 13(1):e0191174. PubMed ID: 29351313
[TBL] [Abstract][Full Text] [Related]
44. Educating physicians about women's health. Survey of Canadian family medicine residency programs.
McCall MA; Sorbie J
Can Fam Physician; 1994 May; 40():900-5. PubMed ID: 8038635
[TBL] [Abstract][Full Text] [Related]
45. Induction of abortion with mifepristone (RU 486) and oral or vaginal misoprostol.
el-Refaey H; Rajasekar D; Abdalla M; Calder L; Templeton A
N Engl J Med; 1995 Apr; 332(15):983-7. PubMed ID: 7885426
[TBL] [Abstract][Full Text] [Related]
46. Updates to the US Food and Drug Administration Regulations for Mifepristone: Implications for Clinical Practice and Access to Abortion.
Simmonds KE; Beal MW; Eagen-Torkko MK
J Midwifery Womens Health; 2017 May; 62(3):348-352. PubMed ID: 28632953
[TBL] [Abstract][Full Text] [Related]
47. Point-of-care ultrasonography in Canadian anesthesiology residency programs: a national survey of program directors.
Mok D; Schwarz SKW; Rondi K
Can J Anaesth; 2017 Oct; 64(10):1023-1036. PubMed ID: 28755100
[TBL] [Abstract][Full Text] [Related]
48. National Organization of Nurse Practitioner Faculties.
Vanderhoef DM; Delaney KR
J Am Psychiatr Nurses Assoc; 2017; 23(2):159-165. PubMed ID: 28076689
[TBL] [Abstract][Full Text] [Related]
49. Mifepristone followed in 24 hours to 48 hours by misoprostol for late first-trimester abortion.
Bracken H; Ngoc NT; Schaff E; Coyaji K; Ambardekar S; Westheimer E; Winikoff B
Obstet Gynecol; 2007 Apr; 109(4):895-901. PubMed ID: 17400851
[TBL] [Abstract][Full Text] [Related]
50. "I just was really scared, because it's already such an uncertain time": Exploring women's abortion experiences during the COVID-19 pandemic in Canada.
Hukku S; Ménard A; Kemzang J; Hastings E; Foster AM
Contraception; 2022 Jun; 110():48-55. PubMed ID: 35123980
[TBL] [Abstract][Full Text] [Related]
51. A Virtual Community of Practice to Support Physician Uptake of a Novel Abortion Practice: Mixed Methods Case Study.
Dunn S; Munro S; Devane C; Guilbert E; Jeong D; Stroulia E; Soon JA; Norman WV
J Med Internet Res; 2022 May; 24(5):e34302. PubMed ID: 35511226
[TBL] [Abstract][Full Text] [Related]
52. Update on second trimester medical abortion.
Lerma K; Shaw KA
Curr Opin Obstet Gynecol; 2017 Dec; 29(6):413-418. PubMed ID: 28922193
[TBL] [Abstract][Full Text] [Related]
53. Environmental health competencies: a survey of nurse practitioner programs.
Bellack JP; Musham C; Hainer A; Graber DR; Holmes D
AAOHN J; 1996 Jul; 44(7):337-44. PubMed ID: 8852232
[TBL] [Abstract][Full Text] [Related]
54. First and Second-Trimester Surgical Abortion Providers and Services in 2019: Results From the Canadian Abortion Provider Survey.
Renner R; Ennis M; Kean L; Brooks M; Dineley B; Pymar H; Norman WV; Guilbert E
J Obstet Gynaecol Can; 2023 Dec; 45(12):102188. PubMed ID: 37558165
[TBL] [Abstract][Full Text] [Related]
55. Core curriculum and competencies: A multisite analysis of postgraduate training programs for primary care nurse practitioners.
Hicks KE; Rico J; Beauchesne M
J Prof Nurs; 2018; 34(6):454-462. PubMed ID: 30527693
[TBL] [Abstract][Full Text] [Related]
56. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
[TBL] [Abstract][Full Text] [Related]
57. Pharmacy workers in Nepal can provide the correct information about using mifepristone and misoprostol to women seeking medication to induce abortion.
Tamang A; Puri M; Lama K; Shrestha P
Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):104-15. PubMed ID: 25702074
[TBL] [Abstract][Full Text] [Related]
58. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
Ngoc NT; Blum J; Raghavan S; Nga NT; Dabash R; Diop A; Winikoff B
Contraception; 2011 May; 83(5):410-7. PubMed ID: 21477682
[TBL] [Abstract][Full Text] [Related]
59. Training in aspiration abortion care: An observational cohort study of achieving procedural competence.
Levi A; Goodman S; Weitz T; AbiSamra R; Nobel K; Desai S; Battistelli M; Taylor D
Int J Nurs Stud; 2018 Dec; 88():53-59. PubMed ID: 30196123
[TBL] [Abstract][Full Text] [Related]
60. Mifepristone (RU 486) in the United States. What does the future hold?
Rosenfield A
N Engl J Med; 1993 May; 328(21):1560-1. PubMed ID: 8479494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
